Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead ...

Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

North Yorkshire Council has been criticised by anti-obesity charities for making £90,000 from the sale of junk food and fizzy drinks at Harrogate district leisure centres. Council-owned leisure ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Expensive processed meals and fatty, chemical-laden treats are highly profitable, as a trip to any supermarket, where they ...

Gemiglo is the first domestic diabetes medication brand to surpass 1 trillion won in sales. Sales of the Gemiglo product line ...